Open label randomized phase II, multicentre, pilot study to evaluate safety and efficacy of the combination of cetuximab and concomitant-boost accelerated radiotherapy followed or not by a complementary treatment with cetuximab in patients with locally advanced oropharynx squamous cell carcinoma

Trial Profile

Open label randomized phase II, multicentre, pilot study to evaluate safety and efficacy of the combination of cetuximab and concomitant-boost accelerated radiotherapy followed or not by a complementary treatment with cetuximab in patients with locally advanced oropharynx squamous cell carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Oropharyngeal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jun 2010 Efficacy results have been presented at ASCO 2010.
    • 29 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top